UCB Sa operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Lonza Group AG
sales of 3.80 billion Swiss Francs [US$3.75 billion]
of which 57%
was Specialty Ingredients),
(195.31 billion Russian Rubles [US$3.27 billion]
of which 81%
was Distribution), and
based in the United Kingdom
(£4.21 billion [US$5.14 billion]
of which 100%
was Pharmaceuticals & Genetic Therapies).
UCB Sa reported sales of 3.88 billion Euro (US$4.10 billion)
December of 2015.
increase of 15.9%
versus 2014, when the company's sales were 3.34 billion Euro.